Skip to main

Seagen's ADC Patent Voided in Dispute with Daiichi Sankyo


The US Patent and Trademark Office has invalidated Seagen's patent (No. 10,808,039), which covers ADC technologies including auristatin peptides linked with antibodies using a specific linker technology. This decision marks a critical point in Seagen’s ongoing legal dispute with Daiichi Sankyo.

Read more